Axogen Inc vs iShares MSCI Malaysia ETF — how do they compare? Axogen Inc trades at $49.11 (market cap $2.61B), while iShares MSCI Malaysia ETF trades at $28.28. The key difference: Axogen Inc is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | EWM | |
|---|---|---|
Market Cap | $2.61B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $48.48 | $30.42 |
52-Week Low | $14.16 | $24.73 |
Enterprise Value | $2.52B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →